Statements (34)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antiviral drug
protease inhibitor |
| gptkbp:approvalYear |
1995
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
gptkb:J05AF05
|
| gptkbp:bioavailability |
80–87%
|
| gptkbp:brand |
gptkb:Combivir
gptkb:Epivir gptkb:Epivir-HBV gptkb:Kivexa gptkb:Trizivir |
| gptkbp:CASNumber |
gptkb:134678-17-4
|
| gptkbp:developedBy |
GlaxoSmithKline
|
| gptkbp:eliminationHalfLife |
5–7 hours
|
| gptkbp:excretion |
renal
|
| gptkbp:hasMolecularFormula |
gptkb:C8H11N3O3S
|
| https://www.w3.org/2000/01/rdf-schema#label |
lamivudine
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits reverse transcriptase
|
| gptkbp:metabolism |
minimal
|
| gptkbp:pregnancyCategory |
C (US)
B3 (Australia) |
| gptkbp:proteinBinding |
<36%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea fatigue headache |
| gptkbp:usedFor |
HIV infection
chronic hepatitis B |
| gptkbp:WHOModelListOfEssentialMedicines |
yes
|
| gptkbp:bfsParent |
gptkb:NRTIs
gptkb:Hepatitis_B |
| gptkbp:bfsLayer |
5
|